Methods
The study was approved by the University of Wuerzburg institutional ethics committee. The approval contained the explicit assignment of an intermediate analysis of the safety and effectiveness of the study intervention after it was applied in 4 cases. To detect a significant increase of CBF by an elevation of PaCO 2 from 40 to 50 mm Hg and from 40 to 60 mm Hg, a number of 6 patients was calculated. This calculation was based on the experimental data of Diringer et al. 5 and Schmieder et al. 20 This Phase 1 clinical trial was registered with the ClinicalTrials.gov database (http://clinicaltrials.gov), and its registration number is NCT01799525.
Inclusion Criteria
The patients were included in the study on Day 4 after SAH. They were eligible for recruitment if they had suffered severe aSAH and had undergone placement of an external ventricular drainage device due to occlusive hydrocephalus as well as early treatment of the ruptured aneurysm (coiling or clipping) within the first 72 hours after rupture. The severity of aSAH was classified a) by the 5-grade clinical classification introduced by Hunt and Hess, 12 and b) by the 4-grade radiological classification of Fisher. 7, 8 Only patients of poor clinical grades (Hunt and Hess Grade III-V) and diffuse thick subarachnoid blood clots (Fisher Grade 3) with or without intraventricular or intracerebral hemorrhage were included in the study. As all patients who met the inclusion criteria were unable to give informed consent, the rapid appointment of a legal guardian was obtained, and this individual's written consent was required for inclusion into the study.
Exclusion Criteria
Patients were not eligible for inclusion if they were under 18 years of age, suffered from chronic obstructive pulmonary disease, or had an intracranial pressure (ICP) of more than 20 mm Hg. The criteria to interrupt the trial intervention were an arterial pH value under 7.25, an ICP higher than 25 mm Hg for more than 2 minutes, and spontaneous breathing under controlled hypoventilation with constant analgosedation.
Respirator Settings
All patients were intubated and mechanically ventilated in a volume-controlled ventilation mode (SERVO-i, Maquet GmbH). Prior to the intervention, PaCO 2 values were kept within the normal range (36-44 mm Hg). Before the beginning of the PaCO 2 intervention, arterial blood gases were obtained for baseline. At first, the respiratory minute ventilation was increased by increasing the respiratory rate to reach a PaCO 2 level of 30 mm Hg. Subsequently, the respiratory rate and minute ventilation were reduced gradually in 15-minute intervals to reach target PaCO 2 values of 40, 50, and 60 mm Hg. Thereafter, the respirator settings were returned to baseline parameters to obtain normal PaCO 2 levels. Apart from the respiratory rate, all other respirator settings (tidal volume, inspiratory-expiratory ratio, and inspiratory fraction of oxygen) remained unchanged.
Arterial Blood Gases and Hemodynamic Parameters
A 15-minute period was allowed for equilibration between each modification. Arterial blood gases, hemoglobin, glucose, sodium, and potassium concentrations were measured by standard blood gas electrodes (RapidLab 700, Siemens Health Care). Heart rate, mean arterial blood pressure, and peripheral oxygen saturation were continuously monitored throughout the intervention period.
Monitoring of Cerebral Vasospasm and Cerebral Infarction
Transcranial Doppler sonography (TCD) of the intracranial vessel trunks was performed every day. For measurement of the internal carotid artery and the middle and anterior cerebral arteries, a temporal ultrasound window was used. For measurement of the basilar artery, a suboccipital ultrasound window was used. A mean flow velocity over 140 cm/sec in the anterior circulation and over 90 cm/sec in the basilar artery was considered indicative of cerebral vasospasm. CT and perfusion CT scans were performed at 3-day intervals to monitor for newly appearing hypodensities in the brain tissue representing secondary infarction and areas with perfusion deficits. In case of suspected vasospasm, the patients were transferred to the angiography suite for diagnostic angiography. If short-segment proximal vasospasm was detected, balloon dilation was performed. In case of diffuse peripheral vasospasm, pharmacological vasospasmolysis with nimodipine was performed.
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Target Parameters
Cerebral blood flow was measured by an intracerebral thermodilution probe (Q-Flow 500, Hemedex) positioned in the right frontal cortex 1.5 cm anterior to the external ventricular drain and was monitored by a Bowman Perfusion Monitor (Hemedex). Cerebral tissue oxygen saturation (S ti O 2 ) was measured by near-infrared spectroscopy (NIRS) (INVOS, Covidien). The probes were attached bilaterally on the forehead skin. At the beginning of each intervention, a baseline value was established, to which the following measurements were compared.
Protocol and Statistical Analysis
For the baseline value, and each further measurement point, CBF, ICP, S ti O 2 , respirator settings, arterial blood gas values, and hemodynamic parameters were written into an examination protocol. The values were transferred to electronic datasheets. Testing for normal distribution was performed by a D'Agostino-Pearson normality test. Since normality testing was not passed for all data columns and measurement points, a Friedman test was used for nonnormally distributed data; this was followed by post hoc testing using Dunn's multiple comparison test. Statistical analyses were performed using GraphPad Prism 4.0 statistical software.
Results
All patients had suffered from SAH and had poor clinical grades. One patient was classified as Hunt and Hess Grade III, 3 patients as Grade IV, and 2 as Grade V.
All patients had thick diffuse subarachnoid blood clots, representing Grade 3 on the Fisher scale. Altogether, the trial intervention was performed 60 times in these 6 patients (Table 1) .
Clinical and Radiological Course
All patients had developed early occlusive hydrocephalus and were treated with external ventricular drainage. According to the study protocol and ethics vote, the aneurysm was occluded within the first 3 days. None of the 6 patients regained appropriate consciousness for extubation and spontaneous ventilation, so anesthesia was continued and an intracerebral probe was placed for CBF measurement. Thus, these patients met the inclusion criteria for the study. Since the patient in Case 4 intermittently had ICP values above 20 mm Hg on Days 4 and 5 after SAH, the first trial intervention was performed on Day 6. Daily TCD showed a significant increase of mean flow velocity in each patient. In 5 of 6 cases the patients underwent additional angiographic examinations during the course of the hospital stay due to suspected vasospasm. The angiographic findings are presented in Table 2 . Serial CT scans did not show evidence of secondary infarction in any of the patients.
Side Effects
Since all patients were being treated with external ventricular drainage prior to entry into the study and the device was kept open for continuous CSF drainage during the intervention, no patient experienced a relevant elevation of ICP. However, the potential elevation of ICP was reflected in a surplus drainage of CSF when PaCO 2 was elevated to 50 and 60 mm Hg. During the decrease of PaCO 2 to 30 mm Hg the CSF drainage was 2.2 ± 2.8 ml over 15 minutes. During the increase of PaCO 2 to 40, 50, and 60 mm Hg, the CSF drainage was 4.4 ± 4.8, 7.7 ± 6.1, and 9.8 ± 7.2 ml over 15 minutes, respectively; PaO 2 was not markedly influenced by the alterations of the respirator settings.
Ventilation and PaCO 2
The baseline PaCO 2 was 39.1 ± 3.9 mm Hg at a respiratory minute ventilation of 7.8 ± 1.3 L/min. After increasing the respiratory rate and minute ventilation to 12.2 ± 2.0 L/min for 15 minutes, PaCO 2 decreased to 32.1 ± 1.4 mm Hg. Thereafter, the respiratory minute ventilation was decreased in 15-minute intervals to 6.4 ± 1.5, 4.3 ± 1.0, and 2.9 ± 0.7 L/min, resulting in PaCO 2 values of 41.1 ± 2.5, 50.1 ± 2.5, and 61.3 ± 4.0 mm Hg, respectively.
Cerebral Blood Flow
The mean baseline CBF measured in the right frontal lobe was 19.0 ml/100 g/min. Hypocapnia (PaCO 2 32.1 ± 1.4 mm Hg) resulted in a decrease of CBF to a mean of 15.1 ml/100 g/min (79% of baseline). Increasing PaCO 2 to 41.1 ± 2.5, 50.1 ± 2.5, and 61.3 ± 4.0 mm Hg resulted in an increase of CBF to 18.7, 23.6, and 27.1 mg/100 g/min, respectively (98%, 124%, and 143% of baseline) (Fig. 1) .
In 30 measurements, the course of CBF was followed for more than 1 hour after the termination of the trial interventions. In this subset of measurements, the mean baseline CBF was 17.3 ml/100 g/min. At PaCO 2 values of 30, 40, 50, and 60 mm Hg, CBF was 13.0 (75% of baseline), 17.1 (99%), 21.0 (121%), and 24.8 (143%). Thereafter, the trial intervention was terminated, and the respirator settings were returned to normal. At 15, 30, 45, and 60 minutes after the respirator was reset to baseline parameters (i.e., 75, 90, 105, and 120 minutes after initiation of the trial), the mean CBF was 24.9 (144%), 22.6 (131%), 20.6 (119%), and 19.3 (112%) (Fig. 2) .
Cerebral Tissue Oxygenation
The baseline S ti O 2 measured by NIRS over the right forebrain was 67.0%. It decreased to 62.0% (93% of baseline) at a PaCO 2 of 32.1 ± 1.4 mm Hg and increased to 65.9% (98% of baseline), 69.7% (104% of baseline), and 74.2% (111% of baseline) at PaCO 2 values of 41.1 ± 2.5, 50.1 ± 2.5, and 61.3 ± 4.0 mm Hg (Fig. 3) . At 15, 30, 45, and 60 minutes after resetting the respirator to baseline parameters, a S ti O 2 of 73.0% (109% of baseline), 70.8% (106% of baseline), 70.0% (104% of baseline) and 67.6% (101% of baseline) was measured (Fig. 4) .
On the left side, the baseline S ti O 2 was 70.5%. It decreased to 66.3% (94% of baseline) at a PaCO 2 of 32.1 ± 1.4 mm Hg and increased to 69.9% (99% of baseline), 73.9% (105% of baseline), and 78.1% (111% of baseline) at PaCO 2 values of 41.1 ± 2.5, 50.1 ± 2.5, and 61.3 ± 4.0 mm Hg (Fig.  3) . At 0.15, 30, 45, and 60 minutes after resetting the res- pirator to baseline parameters, the mean S ti O 2 values were 77.5% (110% of baseline), 74.8% (106% of baseline), 73.0% (104% of baseline), and 71.3% (101%) (Fig. 4) .
Discussion
The present data indicate that CBF and S ti O 2 can be enhanced by graded hypercapnia in patients with highgrade SAH. The effect outlasts the period of hypercapnia and does not turn into a rebound perfusion deficit.
Measurements of CBF and S ti O 2 were conducted by thermodilution and transcutaneous NIRS, respectively. Measurement of the regional CBF by the thermodilution method is based on the temperature difference between a temperature input and a temperature measurement point. The difference decreases with higher CBF and has been validated by comparison with invasive measurement of brain tissue oxygen tension. 13, 18 NIRS measures the content of oxygenated hemoglobin in tissues and depends on arterial partial pressure of oxygen (PaO 2 ) on the one side 1, 14 and CBF on the other side. 16, 21, 22 Transcutaneous NIRS measurement has been validated by comparison with xenon and perfusion CT. 21, 22 PaCO 2 was the only variable parameter in the present study. In particular, the arterial oxygen saturation and PaO 2 remained constant. We recorded a nonsignificant but marked difference between the left and right NIRS measurements, which is probably due to technical reasons. In particular, the sub- arachnoid blood distribution over the frontal lobes might influence the transcranial NIRS measurement that reads the presence of hemoglobin. Apart from one right middle cerebral artery aneurysm (Case 1), all aneurysms in this series had domes directed to the left side causing a corresponding increase in subarachnoid blood on that side.
In the present study, the trial end points, CBF and brain tissue oxygenation (S ti O 2 ), were gathered by measurements in only one or two points, respectively, which makes it susceptible to false-negative measurements. The CBF probe was placed into the border zone of the right middle and anterior cerebral arteries in an attempt to cover 2 vascular territories. The NIRS probes were placed bilaterally on the forehead over the territories supplied by the anterior cerebral artery. The CBF probe was placed in a noneloquent area. The placement of the NIRS probes was chosen on the basis of practical considerations; placement on the forehead does not require additional removal of hair and allows the probe to adhere to a broad and flat skin area. Since both CBF and S ti O 2 measurement are regional measurements, a redistribution of blood in terms of a "steal phenomenon" into other territories that are not monitored cannot be excluded. Our measurements do not suggest a left-right shift since relative changes of bilateral NIRS measurements had an absolutely parallel course. In contrast, the fact that all PaCO 2 interventions resulted in an elevation of CBF and bilateral S ti O 2 rather suggests that the elevation of PaCO 2 causes a global increase of brain perfusion and oxygen supply, even in the territory supplied by the most affected vessel and within the period of maximum vascular narrowing. Ideally, each vascular territory should be supplied with a probe, but this was not justifiable in this clinical study. Thus, it is possible that territories with reduced CO 2 reactivity may have been missed by the monitoring tools. In the 6 cases reported here, maximum elevations of flow velocities in TCD and maximum angiographic vessel narrowing were found in the territories supplied by the internal carotid arteries that were covered by the monitoring probes.
The CBF and bilateral NIRS measurements showed a concomitant decrease and increase during the period of hypercapnia as well as after the resetting of the respirator to baseline parameters. Therefore, it can be concluded that both monitoring tools-invasive CBF measurement as well as noninvasive transcutaneous NIRS-are suitable methods for following short-term changes of CBF. Both are methods of bedside monitoring and, in comparison with TCD or radiological examinations, allow continuous measurement of relative changes of CBF.
Several days after aSAH, a variety of local factors lead to contraction and finally to structural changes of the vessel wall.
11 However, arterial vasospasm seems not to be the only factor for the development of delayed cerebral ischemia (DCI) after aSAH. DCI can occur without significant cerebral vasospasm 2 and many patients with arterial vasospasm do not develop DCI. 9 Dreier et al. 6 and Pluta et al. 17 suggested a double-hit model of secondary ischemia in which ion disturbances and hypermetabolism are superimposed on arterial narrowing and, in combination, cause DCI. Although the etiology of DCI is not exactly known, all pathophysiological factors are likely to finally turn into a discrepancy between the supply and demand of oxygen in the brain. The CO 2 reactivity of CBF after SAH has been examined by several groups in experimental models and in SAH patients. In animal studies, Diringer et al. and Schmieder et al. demonstrated that the reactivity of CBF upon changes of PaCO 2 is still intact after SAH, whereas autoregulation on blood pressure changes is deranged after SAH. 5, 20 Hassler and Chioffi found that downstream of segmental vasospasm, small peripheral vessels are in a compensatory state of near-maximum dilation. They concluded that the dilatational capacity of small blood vessels during hypercapnia is low and hyperventilation is hazardous because a contraction of peripheral vessels may rapidly cause ischemia in the presence of a spastic proximal vessel segment. 10 Recently, Carrera and coworkers have reported on a clinical trial assessing the predictive value of various extents of CO 2 reactivity of CBF after aSAH. They found that the loss of normal CO 2 reactivity predicts a high risk for the eventual development of DCI. 3 In that study, the end-tidal CO 2 was elevated 6 mm Hg by inhalation of an air-oxygen mixture enriched with 5% CO 2 . The patients who showed only a small increase of CBF were more prone to develop DCI. In our study, hypercapnia was confirmed by arterial blood gas measurement. PaCO 2 was elevated by a mean of 22.0 mm Hg. All patients showed an increase of CBF and S ti O 2 in each measurement after this high increase of PaCO 2 . The therapeutic potential of hypercapnia to enhance CBF after SAH has not been evaluated in humans until now. Schatlo et al. reported no reactivity of CBF upon alterations of PaCO 2 in a primate study of experimental cerebral vasospasm. 19 This is in discordance with our finding in human patients, as we observed reproducible increases of CBF and S ti O 2 upon an elevation of PaCO 2 in all trial interventions, including the days of maximum flow velocities in TCD in all 6 patients (Fig. 5) . The course of CBF and S ti O 2 after the period of hypercapnia indicates that there is a sustained CBF-enhancing effect with a slow return to baseline values and without a rebound effect. The CBF-enhancing effect lasts much longer than the amount of time that would be expected for PaCO 2 to return to baseline values. This sustained effect may be mediated by the CSF pH. Buffer systems influence the CSF pH during the period of hypercapnia, leading to a slow adaptation to an elevated PaCO 2, and may, on the other hand, slow down the recovery of CSF pH. 24 This could result in a delayed return of CBF to baseline. The period of hypercapnia was still relatively short in the present study, as it was the purpose of this study to assess in principle whether hypercapnia can be used to enhance CBF. The optimum duration and intensity of hypercapnia and especially whether longer periods of hypercapnia result in an even more sustained elevation of CBF still need to be investigated. The treatment may be optimized by a longer duration of hypercapnia. In theory, the ideal duration is until CSF starts decreasing again due to the action of buffer systems in blood and CSF. If this length of time is exceeded, a rebound effect can be expected after returning to baseline respirator settings. The next step, a trial assessing this critical time limit, is currently being conducted.
Although the study was planned with strict criteria for patient exclusion and trial termination, we did not have to interrupt a single PaCO 2 intervention or exclude any patient from the study after the beginning. The reproducible elevation of CBF and S ti O 2 , the sustained effect, and the obvious absence of negative side effects in patients who are being treated with external ventricular drainage for ICP compensation suggest a therapeutic potential of hypercapnia in patients with aSAH.
Conclusions
The controlled alteration of PaCO 2 by modification of the respiratory minute ventilation interferes with a very basic physiological regulatory mechanism. The intervention is easy to perform and arterial blood gas levels can be maintained on the basis of repeated arterial blood gas analyses. The present data show that it is safely feasible in SAH patients who are mechanically ventilated. Since increased intracranial blood volume can cause an elevation of ICP and thus may potentially be harmful, hypercapnia should not be induced without continuous CSF drainage or at least continuous ICP measurement. The enhancement of CBF and S ti O 2 by this nonpharmacological therapeutic approach of controlled hypercapnia is highly reproducible and sustained and might yield a high therapeutic potential in this state of critical brain perfusion.
